BIOCON SDN BHD

BIOCON SDN BHD is a Malaysian subsidiary of the Indian biopharmaceutical company, Biocon Limited. While BIOCON SDN BHD itself is based in Malaysia, its parent company, Biocon Limited, is a prominent Indian enterprise.

It is a Manufacturer.

BIOCON SDN BHD, located in Johor, Malaysia, operates as a manufacturing facility primarily focused on the production of biopharmaceutical products, including insulins, for global markets. It plays a significant role in the Biocon Group's global manufacturing and supply chain.

Biocon Limited, the parent company headquartered in Bengaluru, India, is a leading innovation-led global biopharmaceutical company. It specializes in the research, development, manufacturing, and commercialization of biopharmaceuticals, including biosimilars, novel biologics, and complex generics. Biocon Limited operates extensive manufacturing facilities in India and other locations, producing a wide range of products for diabetes, oncology, immunology, and other therapeutic areas. The company is recognized for its commitment to making affordable biopharmaceuticals accessible worldwide.

Biocon Limited, an Indian biopharmaceutical company, manufactures and sells a range of products primarily in the areas of biosimilars, biopharmaceuticals, and branded formulations. Their product portfolio includes:

Biosimilars:

Insulin glargine (for diabetes)

Insulin aspart (for diabetes)

Recombinant human insulin (for diabetes)

Trastuzumab (for breast cancer)

Bevacizumab (for various cancers)

Adalimumab (for autoimmune diseases)

Pegfilgrastim (for chemotherapy-induced neutropenia)

Branded Formulations (covering therapeutic areas like diabetes, oncology, immunology, and nephrology):

CANMAb (Trastuzumab biosimilar)

BIOMAb-EGFR (Nimotuzumab, for head and neck cancer)

ALZUMAb (Itolizumab, for psoriasis)

TACROLIMUS (immunosuppressant)

EVEROLIMUS (immunosuppressant and anticancer)

MYCOPHENOLATE MOFETIL (immunosuppressant)

Various small molecule formulations for diabetes, oncology, and other chronic diseases.

Biopharmaceutical APIs and Generics:

Active Pharmaceutical Ingredients (APIs) for various drugs.

Generic formulations for a wide range of therapeutic indications.